Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 11/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14891041 | 0.99 | ENPP2 (0.56) | ENPP2MAPTKDM4ECYP1A2CYP3A4 | |
| SCHEMBL17486946 | 0.78 | HDAC1 (0.38) | ENPP2KDM4EHTR6HTR2A | |
| SCHEMBL47769 | 0.77 | ENPP2 (0.75) | ENPP2 | |
| SCHEMBL46620 | 0.75 | ENPP2 (0.78) | ENPP2 | |
| SCHEMBL14891139 | 0.74 | ENPP2 (0.87) | ENPP2 | |
| SCHEMBL14891275 | 0.74 | ENPP2 (0.84) | ENPP2 | |
| SCHEMBL14931525 | 0.74 | ENPP2 (0.82) | ENPP2 | |
| Hydrochloric Acid SCHEMBL30841866 | 0.74 | ENPP2 (0.38) | ENPP2 | |
| SCHEMBL14891145 | 0.73 | ENPP2 (1.00) | ENPP2 | |
| SCHEMBL14891826 | 0.73 | ENPP2 (1.00) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3002285-B1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-9974777-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9862721-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-9636330-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-2592081-B1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-2687531-B1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-9353113-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-31 | — | — | US | disclosed |
| EP-3002285-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-20160031884-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20150231118-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-20 | — | — | US | disclosed |
| US-9006246-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-2687531-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20130345426-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-26 | — | — | US | disclosed |
| EP-2592081-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031884-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | ENPP2 1/4885MAPT 2330/4885KDM4E 4004/4885 |
| US-20130345426-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | ENPP2 1/4885MAPT 2330/4885KDM4E 4004/4885 |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | ENPP2 1/4885MAPT 2387/4885KDM4E 3970/4885 |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | ENPP2 1/4885MAPT 2330/4885KDM4E 4004/4885 |
| US-20150231118-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | ENPP2 1/4885MAPT 2330/4885KDM4E 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.